biosimilar drugs can be a hard sell – SFGate

[ad_1] Big-name drugmakers want to profit from selling lower-priced copies of rivals’ expensive biotechnology drugs. Patients and doctors want to pay less for medicine. Getting those two sides together is harder than it looks. Part of the problem: a web of relationships between drug companies and insurers that shields incumbent…

Biosimilars Come to Community Pharmacy – ModernMedicine

[ad_1] The long-awaited wave of biosimilar biologic agents is finally moving into community pharmacy. PBMs and payers are encouraging patients to move from the familiar long-acting insulin Lantus (insulin glargine, Sanofi) to Basaglar (insulin glargine, Lilly), approved by the FDA in late 2016. The cost difference between the two is…